Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Meyer

Showing results (491-500 of 510) with videos related to

Pageof 51
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 5, 2024
Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III TrialDaniel H Palmer, Richard Jackson, Christoph Springfeld, et al.
British Journal of Sports Medicine|October 24, 2020
Infographic. UEFA expert group 2020 statement on nutrition in elite footballJames Collins, Ronald John Maughan, Mike Gleeson, et al.
Circulation|February 8, 2017
Defined Engineered Human Myocardium With Advanced Maturation for Applications in Heart Failure Modeling and RepairMalte Tiburcy, James E Hudson, Paul Balfanz, et al.
Lancet (London, England)|January 29, 2017
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trialJohn P Neoptolemos, Daniel H Palmer, Paula Ghaneh, et al.
Hepatology (Baltimore, Md.)|November 8, 2019
Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based ApproachGuohong Han, Sarah Berhane, Hidenori Toyoda, et al.
Gastroenterology|September 15, 2022
Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular CarcinomaPhilipp K Haber, Florian Castet, Miguel Torres-Martin, et al.
Journal of Clinical Immunology|May 5, 2022
Early and Rapid Identification of COVID-19 Patients with Neutralizing Type I Interferon Auto-antibodiesBengisu Akbil, Tim Meyer, Paula Stubbemann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2020
MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I TrialDebashis Sarker, Ruth Plummer, Tim Meyer, et al.
JAMA Surgery|September 5, 2019
Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy TrialRobert P Jones, Eftychia-Eirini Psarelli, Richard Jackson, et al.
Cancer Discovery|October 3, 2019
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular CarcinomaRichard D Kim, Debashis Sarker, Tim Meyer, et al.
Pageof 51

Showing results (491-500 of 510) with videos related to

Sort By:
Pageof 51
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 5, 2024
Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III TrialDaniel H Palmer, Richard Jackson, Christoph Springfeld, et al.
British Journal of Sports Medicine|October 24, 2020
Infographic. UEFA expert group 2020 statement on nutrition in elite footballJames Collins, Ronald John Maughan, Mike Gleeson, et al.
Circulation|February 8, 2017
Defined Engineered Human Myocardium With Advanced Maturation for Applications in Heart Failure Modeling and RepairMalte Tiburcy, James E Hudson, Paul Balfanz, et al.
Lancet (London, England)|January 29, 2017
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trialJohn P Neoptolemos, Daniel H Palmer, Paula Ghaneh, et al.
Hepatology (Baltimore, Md.)|November 8, 2019
Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based ApproachGuohong Han, Sarah Berhane, Hidenori Toyoda, et al.
Gastroenterology|September 15, 2022
Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular CarcinomaPhilipp K Haber, Florian Castet, Miguel Torres-Martin, et al.
Journal of Clinical Immunology|May 5, 2022
Early and Rapid Identification of COVID-19 Patients with Neutralizing Type I Interferon Auto-antibodiesBengisu Akbil, Tim Meyer, Paula Stubbemann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2020
MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I TrialDebashis Sarker, Ruth Plummer, Tim Meyer, et al.
JAMA Surgery|September 5, 2019
Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy TrialRobert P Jones, Eftychia-Eirini Psarelli, Richard Jackson, et al.
Cancer Discovery|October 3, 2019
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular CarcinomaRichard D Kim, Debashis Sarker, Tim Meyer, et al.
Pageof 51